1. Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance
- Author
-
Austin Lin, Ron Bose, Matthew J. Ellis, Yiyu Dong, Charles M. Perou, Loren S. Michel, Rodrigo Franco Gonçalves, Chanpheng Phommaly, Ana M. Gonzalez-Angulo, Jingqin Luo, Rama Suresh, Caroline Bumb, Shuying Liu, Jeiya Shao, Rebecca Aft, Shunqiang Li, Timothy J. Pluard, Robert Crowder, Jeremy Hoog, Robert S. Fulton, Reida G. McDowell, Megha Shiyam Kavuri, Aleix Prat, Wenbin Liu, Crystal Cooper, Stephen N. Johnson, Yu Tao, Dong Shen, Therese Giuntoli, Elaine R. Mardis, Christopher J. Miller, Christopher A. Maher, Joshua F. McMichael, Li Lin, Shaomeng Wang, Katherine DeSchryver, Richard Wilson, Thomas B. Mooney, Li Ding, Michael Naughton, Gordon B. Mills, R.T. Kitchens, Dave Larson, and Cynthia X. Ma
- Subjects
Gerontology ,YAP1 ,Cancer Research ,business.industry ,medicine.drug_class ,Cancer ,medicine.disease ,Transactivation ,Breast cancer ,Oncology ,Estrogen ,Cancer research ,Endocrine system ,Medicine ,business ,Estrogen receptor alpha ,Hormone - Abstract
Deeper understanding the mechanisms by which luminal-type breast cancer develops resistance to endocrine therapy and development of novel strategies to treat these patients requires model systems recapitulate human breast cancer as accurately as possible. An increasing body of work suggests patient derived xenografts (PDX) may represent an informative model for development of novel therapeutics. We therefore established seven xenograft tumor lines from late-stage breast cancer patients with estrogen positive (ER+) disease. To date five ER+ PDX lines have been tested for responses to estradiol treatment in overiectomized NOD/SCID mice. Three showed estradiol independent-growth, one estrogen-stimulated growth and in one estradiol-induced a regression. These patterns mimicked the clinical phenotypes of each patient, tracking survival and responses to serial endocrine treatments. To define new mechanisms for resistance, whole genome DNA sequencing, RNA sequencing and Reverse Phase Protein Assay analysis was conducted. These studies identified an ESR1/YAP1 balanced translocation in a PDX model and tumor of origin showing low levels of ER, paradoxical high level expression form luminal genes and extreme ET resistance. The ESR1 YAP1 fusion maintained the N terminal DNA binding motif of ESR1, but the hormone binding and AF2 motifs were replaced with the C terminal transactivation domain of YAP1. Expression ESR1 YAP1 in ER+ breast cancer models down-regulated ER and induced estrogen independent growth. PDX endocrine phenotypes parallel tumor of origin responses to endocrine therapy and revel novel mechanism for endocrine therapy resistance. Citation Format: Matthew J. Ellis, Shunqiang Li, Dong Shen, Li Ding, Robert Crowder, Jeiya Shao, Rodrigo Goncalves, Yu Tao, Jingqin Luo, Aleix Prat, Wenbin Liu, Ana Maria Gonzalez-Angulo, Shuying Liu, Joshua F. McMichael, Chris Miller, Dave Larson, Robert S. Fulton, Tom Mooney, Jeremy Hoog, Li Lin, Therese Giuntoli, Caroline Bumb, Crystal Cooper, Rebecca Aft, Robert T. Kitchens, Stephen N. Johnson, Chanpheng Phommaly, Megha Shiyam Kavuri, Katherine DeSchryver, Austin Lin, YiYu Dong, Cynthia X. Ma, Timothy Pluard, Michael Naughton, Ron Bose, Rama Suresh, Reida G. McDowell, Loren Michel, Richard Wilson, Shaomeng Wang, Christopher Maher, Gordon B. Mills, Charles Perou, Elaine R. Mardis. Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr LB-265. doi:10.1158/1538-7445.AM2013-LB-265
- Published
- 2013
- Full Text
- View/download PDF